Skip to main content

JAK Inhibitors in Difficult Still’s Disease

Aug 05, 2022 9:57 am

A small retrospective study suggests that patients with difficult to treat adult-onset Still's disease (AOSD) or sytemic juvenile idiopathic arthritis (sJIA) may respond well to JAK inhibitor (JAKi) agents - presumable by blocking pro-inflammatory cytokines, notably IL-6 and IFN.

Patients with sJIA or AOSD were gathered based on a national survey conducted in the departments of rheumatology, paediatric rheumatology and internal medicine of French hospitals.

A total of 9 patients (7 AOSD, 2 sJIA) with an inadequate response to corticosteroids, DMARDs or biologics. Jak inhibitor use included Baricitinib (5 patients), ruxolitinib in 2, tofacitinib in 2, and upadacitinib in 1. A JAKi was associated with anakinra and corticosteroids in one patient, and with methotrexate, anakinra and corticosteroids in another.

With a median follow-up of 16 months, 2/9 were in complete remission, 3/9 partial response and 4/9 treatment failure. At the last visit, corticosteroids could be decreased but not stopped.

These observations say that JAKi agents may be an option for some difficult-to-treat Still’s disease, but an unmet need remains for others\.

stillsNow cTA


StillsNow Calculator
The author has no conflicts of interest to disclose related to this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.